Prognostic factors in metastatic breast cancer: Successes and challenges toward individualized therapy

Journal of Clinical Oncology

Volumn 26, Issue 22, 2008, Pages 3660-3662

  Andreopoulou, Eleni ^a   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAPATINIB; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB; ANTINEOPLASTIC AGENT; TUMOR MARKER;

BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL GROWTH; CLINICAL DECISION MAKING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENOTYPE; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MEDICAL RESEARCH; METASTASIS; NOTE; PATIENT SELECTION; PHENOTYPE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; TUMOR GENE; BREAST TUMOR; CANCER STAGING; CHEMISTRY; DECISION SUPPORT SYSTEM; FEMALE; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DECISION SUPPORT SYSTEMS, CLINICAL; DECISION SUPPORT TECHNIQUES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM METASTASIS; NEOPLASM STAGING; PATIENT SELECTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 49249107696     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.1026     Document Type: Note

References (11)

1. Hortobagyi GN, Smith TL, Legha SS, et al: Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1:776-786, 1983
2. Tamoxifen for early breast cancer: An overview of the randomized trials - Early Breast Cancer Trialists' Collaborative Group. Lancet 351:1451-1467, 1998
3. Shou J, Massarweh S, Osborne CK, et al: Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96:926-935, 2004
4. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000
5. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
6. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
7. Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
8. Nagata Y, Lan KH, Zhou X, et al: PTEN activation contributes to tumor inhibition by trastuzumab and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117-127, 2004
9. Meng S, Tripathy D, Shete S, et al: HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 101:9393-9398, 2004
10. Rouzier R, Rajan R, Wagner P, et al: Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A 102:8315-8320, 2005
11. Cristofanilli M, Budd GT, Ellis MJ, et al: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781-791, 2004